Topic: Parkinson's disease
Acadia was stung hard after its schizophrenia hopes for Nuplazid fell flat back in late July. Fortunately, dementia-related psychosis shows promise.
HiFiBiO raises $67 million in series C. Kyowa Kirin wins long-awaited FDA nod for Parkinson's drug Nourianz. SEBI's initial probe clears Sun Pharma.
Spurned by the FDA in 2008, Kyowa Kirin's istradefylline, to be sold as Nourianz, has secured the U.S. go-ahead as an add-on Parkinson's drug.
With psychosis med Nuplazid facing a DOJ probe and schizophrenia flop, Acadia hopes a new round of TV ads will help court more patients.
Acadia Pharmaceuticals is taking Parkinson’s disease education on the road in a partnership with the Michael J. Fox Foundation.
After a two-and-a-half-year wait for impulse-control warnings on six dopamine drugs, a watchdog group sued to force FDA action.
Acadia Pharmaceuticals had to defend its Nuplazid safety last year, and now the drugmaker faces a DOJ probe into its marketing.
When doctors first diagnose Parkinson’s patients, their main focus is motor control. And that gives Acadia, maker of Nuplazid, a big job to do.
Acorda has moved its entire salesforce over from Ampyra to new launch Inbrija. But it’s not relying solely on that team to get the ball rolling.
Acorda has pulled off a crucial approval for Parkinson’s drug Inbrija, but that doesn’t mean the company is out of the woods.